Aciclovir extended release - Vectans Pharma

Drug Profile

Aciclovir extended release - Vectans Pharma

Alternative Names: Aciclovir - Onxeo; Aciclovir extended release - Onxeo; Aciclovir Lauriad®; Aciclovir muco-adhesive buccal tablet - Onxeo; Acyclovir extended release - Onxeo; Acyclovir Lauriad® 50mg (Sitavir) - Onxeo; BA 021; Labiriad; Sitavig; Sitavir®

Latest Information Update: 04 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioAlliance Pharma
  • Developer Cipher Pharmaceuticals; Vectans Pharma
  • Class Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Herpes labialis

Highest Development Phases

  • Marketed Herpes labialis

Most Recent Events

  • 31 Jul 2017 Vectans Pharma acquires Aciclovir extended release from Onxeo
  • 16 Feb 2016 Preregistration for Herpes labialis (Reccurent) in Canada (Buccal) before February 2016
  • 16 Feb 2016 Health Canada accepts NDA for acyclovir extended release for Herpes labialis (Recurrent) for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top